Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
This study aims to investigate the role of clinical pharmacist in the development of a pharmaceutical care program for patients with Acute coronary syndrome tailored to their specific learning needs and their cultural context, and to verify the program's effects on physiological factors and recurrent symptoms or cardiac events.
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| control group | No Intervention | will receive standard care by physician in attendance | |
| intervention group | Active Comparator | will be supplied by clinical pharmaceutical care services provided by the clinical pharmacist plus standard care by physician in attendance. |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| pharmaceutical care service | Behavioral |
|
|
| Measure | Description | Time Frame |
|---|---|---|
| Change in the level of patient education about disease, drugs and lifestyle modification using coronary artery disease education questionnaire (CADE-Q) | at baseline and after three months | three months |
| Change in the number of solved drug-related problems | assessment of drug-related problems at baseline and solving them during three months | three months |
| Assessment of medications adherence: (Eight-item Morisky adherence questionnaire). | at baseline and after three months | three months |
| Measure | Description | Time Frame |
|---|---|---|
| Assessment of quality of life: (36-items self-care Health survey (SF-36)). | at baseline and after three months | three months |
| Assessment of smoker's dependence on cigarette smoking: (using the Fagerstrom Test for Nicotine Dependence). |
| Measure | Description | Time Frame |
|---|---|---|
| Change in potassium (mmol/l). | at baseline and after three months | three months |
| Change in sodium (mmol/l). | at baseline and after three months |
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Eman A. Casper, bachelor | Ain Shams University | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Ain Shams University | Cairo | Egypt |
| PubMed Identifier | Type | Citation | Retractions |
|---|---|---|---|
| 35701314 | Derived | Ahmed Casper E, Mohmed El Wakeel L, Ayman Saleh M, Hamed El-Hamamsy M. The impact of a comprehensive pharmaceutical care intervention in addition to cardiac rehabilitation program on outcomes of post-acute coronary syndrome patients: A pilot study. Patient Educ Couns. 2022 Oct;105(10):3164-3168. doi: 10.1016/j.pec.2022.06.004. Epub 2022 Jun 10. |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Type | Date | Date Unknown |
|---|---|---|
| Release | Jun 5, 2018 | |
| Reset | Oct 18, 2018 |
Not provided
Not provided
| Release Date | Unrelease Date | Unrelease Date Unknown | Reset Date | MCP Release Number |
|---|---|---|---|---|
| Jun 5, 2018 | Oct 18, 2018 |
| ID | Term |
|---|---|
| D054058 | Acute Coronary Syndrome |
| ID | Term |
|---|---|
| D017202 | Myocardial Ischemia |
| D006331 | Heart Diseases |
| D002318 | Cardiovascular Diseases |
| D014652 | Vascular Diseases |
Not provided
Not provided
| ID | Term |
|---|---|
| D010593 | Pharmaceutical Services |
| ID | Term |
|---|---|
| D006296 | Health Services |
| D005159 | Health Care Facilities Workforce and Services |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
at baseline and after three months
| three months |
| Change in heart rate [HR] (Bpm). | at baseline and after three months | three months |
| Change in Lipid profile : total cholesterol (mg/dl), triglycerides(mg/dl), and low density lipoprotein cholesterol(mg/dl), high density lipoprotein (mg/dl) | at baseline and after three months | three months |
| Change in levels of fasting blood glucose (mg/dl) | at baseline and after three months | three months |
| Change in systolic and diastolic blood pressure [BP] (mmHg). | at baseline and after three months | three months |
| three months |
| Change in serum creatinine (mg/dl). | at baseline and after three months | three months |
| Change in waist circumference (cm). | at baseline and after three months | three months |
| Change in Liver function tests: aspartate aminotransferase enzyme (AST) (u/l), alanine aminotransferase (ALT) (u/l) | at baseline and after three months | three months |
| Change in Kidney function tests : serum urea (mg/dl). | at baseline and after three months | three months |
| Change in anthropometric measurements (body mass index [BMI] (Kg/m^2)) | at baseline and after three months | three months |